VOL.51 NO.6
JUNE 2003
JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Crit Care Med, 163: 1730-1754, 2001 10) Bartlett JG et al: Practice guidel ines for the management of community-acquired pneumonia in adults. Clin Infect Dis, 31: 347-382, 2000 11) Fine MJ et al: A prediction rule to identify low risk patients with community-acquired pneumonia. N Engl J Med, 336: 243-250, 1997 12) Campbell GD et al: Hospital-acquired pneumonia in adults; Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. Am J Respir Crit Care Med, 153: 1711-1725, 1995
VOL.51 NO.6
JUNE 2003
VOL.51 NO.6
JUNE 2003
VOL.51 NO.6 4) De Pauw BE, Deresinski SC, Feld R, et al. Ceftazidime compared to piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. Ann Intern Med: 120: 834-44, 1994 5) Breen J, Ramphal R. Cometta A, et al. Cefepime versus ceftazidime as empiric therapy of febrile neutropenic patients. In: Klastersky J, ed. Febril neutropenia. Berlin: Springer-Verlag, 63-74. 1997 6) Ramphal R. Clinical experience with single agent and combination regimens in the management of infection in the febr ile neutropenia patient. AM J MED 100, 6A, 83, 1996. 7) Cometta A, Calandra T, Gaye H, et al. Monotherapy with meropenem versus combinatioa therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob
JUNE 2003 Agents Chemother; 40:1108-15. 1996 8) The Meropenem Study Group of Leuven, London and Nijmengen: Equivalent efficacies of meropenem and ceftazidime as empirical mono-therapy of febrile neutropenic patients. J Antimicrob Clemother 36:185-200, 1995 9) Hughes W. T., Pizzo P. A., Wade J. C. et al. General guideline for the evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Clinical Infectious Diseases 15 (Suppl 1): S206-215, 1992 10) Hughes W. T., Armstrong D., Bogey G. P. et al. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clinical Infectious Diseases 25: 551-73. 1997 11) Hughes W. T., Armstrong D., Bogey G. P. et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases 34: 730-51. 2002 13) Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identify low-risk febrile neutropenic cancer patients. J Clin Oncol 18: 3038-3051. 2000.
VOL.51 NO.6
JUNE 2003
VOL.51 NO.6
JUNE 2003
VOL.51 NO.6
4) U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Guidance for Industry: Acute Bacterial Meningitis- Developing Antimicrobial Drugs for Treatment. July 1998